Untitled

Pani, S P; Reddy, G. S.; Das, Lalit Kumar; Vanamail, Perumal; Hoti, S.L.; Ramesh, J.; Das, PK

doi:10.1186/1475-2883-1-1

Cited by 50 publications

(49 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their three-arm trials, Pani et al (2002) studied the effects of single treatments with DEC, ALB or DEC-ALB, using patients who had relatively mild microfilaraemias at baseline (with means of 81.3, 77.6 and 79.4 mff/ml, respectively). One year posttreatment, the three treatment arms appeared similar in terms of the prevalence and intensity of microfilaraemia, although, compared with the results of the present study (Fig.…”

Section: Dec or Dec-albendazole Treatment Of Childrenmentioning

confidence: 99%

“…There were, however, further and significant reductions in the prevalences of microfilaraemia, in all three treatment arms, during the second year post-treatment (Pani et al, 2004). Unfortunately, Pani et al (2002) did not state the volume of blood collected/ subject, did not describe the method they used to evaluate the prevalence or intensity of microfilaraemia, and did not separate their efficacy results by age-group.…”

Section: Dec or Dec-albendazole Treatment Of Childrenmentioning

confidence: 99%

“…In filariasis-endemic areas outside of subSaharan Africa, the strategy recommended by the WHO to interrupt transmission of the parasites that cause LF is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; at 6 mg/kg) and albendazole (ALB; at 400 mg/subject; Ottesen et al, 1997). Most clinical and field trials investigating the efficacy and tolerance of such DEC-ALB combinations, in bancroftian filariasis, have used adult subjects (Ismail et al, 1998(Ismail et al, , 2001Pani et al, 2002;El Setouhy et al, 2004;Kshirsagar et al, 2004;Fox et al, 2005), and not all of them have included a DEC-only treatment arm, to show that the use of ALB leads to significantly better treatment. In India, Pani et al (2002) included 24 children under 14 years of age in their study group of 54 individuals but did not give separate efficacy results for their adult and paediatric subjects.…”

mentioning

confidence: 99%

“…Most clinical and field trials investigating the efficacy and tolerance of such DEC-ALB combinations, in bancroftian filariasis, have used adult subjects (Ismail et al, 1998(Ismail et al, , 2001Pani et al, 2002;El Setouhy et al, 2004;Kshirsagar et al, 2004;Fox et al, 2005), and not all of them have included a DEC-only treatment arm, to show that the use of ALB leads to significantly better treatment. In India, Pani et al (2002) included 24 children under 14 years of age in their study group of 54 individuals but did not give separate efficacy results for their adult and paediatric subjects. In their recent, community-based study, Fox et al (2005) only studied children but used a relatively short follow-up (6 months) and a relatively insensitive method (the microscopical examination of a 20-ml thick smear) to detect microfilaraemias.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Children and adolescents infected withWuchereria bancroftiin Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine–albendazole

Rizzo

Belo

Lins

et al. 2007

Annals of Tropical Medicine & Parasitology

View full text Add to dashboard Cite

In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.

show abstract

Section: Dec or Dec-albendazole Treatment Of Childrenmentioning

confidence: 99%

Section: Dec or Dec-albendazole Treatment Of Childrenmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Children and adolescents infected withWuchereria bancroftiin Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine–albendazole

Rizzo

Belo

Lins

et al. 2007

Annals of Tropical Medicine & Parasitology

View full text Add to dashboard Cite

show abstract

“…Inspite of the preventive and curative measures adopted by National Filariasis Control Programme (NFCP) it is significantly prelevant in the Indian subcontinent. The filarial survey report of 2002 indicates a staggering 553 million population living in endemic areas in our country [5].…”

Section: Discussionmentioning

confidence: 98%